Preferential Rights Issue /
Alzinova carries out a preferential rights issue of approx. SEK 42.5 million. Further down you will find links to relevant documents, press releases and other information.
The Rights Issue was approved by the Annual General Meeting, held on 18 May 2022.
Alzinova’s goal is to complete the clinical Phase 1b study on Alzheimer’s patients with the therapeutic vaccine ALZ-101 during the period 2022-2023. The company also plans to conduct a follow-up study to the Phase 1b study, which is expected to start in early 2023. This long-term follow-up will, among other things, provide additional information on the long-term safety and tolerability of ALZ-101.
In parallel with the Phase 1b study, Alzinova is preparing and optimizing the conditions for the start of a clinical Phase 2 study of ALZ-101. Alzinova’s goal is to carry out preclinical efficacy and toxicology studies during the period 2022-2024, as well as to develop and scale up the production of the monoclonal antibody ALZ-201. The goal is to be ready prior to the start of a clinical Phase 1b study in Alzheimer’s patients.
The issue proceeds from the rights issue shall primarily be used for:
Completion of the Phase 1b study for ALZ-101
Production of substance and technical material of ALZ-101 prior to Phase 2
Strategic marketing, legal processes, patents and operations
Long-term follow-up study of the Phase 1b study for ALZ-101
The establishment of a manufacturing process for ALZ-201
Preclinical efficiency studies for ALZ-101
The issue proceeds from the exercise of the warrants shall primarily be used for production of technical material and clinical trial material for the Phase 1b study of ALZ-201.
Summarizing terms of the rights issue:
Subscription period: May 30, 2022 – June 13, 2022.
Trade in unit rights: May 30, 2022 – June 8, 2022.
Subscription with preferential rights: For each share owned on the record date the holder will receive one (1) unit right. Four (4) unit rights entail a right to subscribe for one (1) unit. One (1) unit consists of five (5) shares and four (4) Warrants.
Subscription price: SEK 10.50 per unit, corresponding to SEK 2.10 per share. The warrants are offered free of charge.
Issue proceeds: In the event of full subscription in the rights issue, the company will receive approximately SEK 42.5 million before issue costs and in the event of full exercise of all warrants, the company will receive an additional maximum of approximately SEK 51.1 million before issue costs.
Subscription commitments and underwriting commitments: The rights issue is covered to approximately 80 percent through subscription commitments and underwriting commitments.